Angiotensin‐converting enzyme inhibition prevents myocardial infarction‐induced increase in renal cortical cGMP and cAMP phosphodiesterase activities

By  

Fundamental & Clinical Pharmacology, Vol. 29, Iss. 4, 2015-08 ,pp. : 352-361

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of angiotensin II and angiotensin-converting enzyme inhibitors on human myocardium

By Lenz O.   Schmid B.   Kilter H.   La Rosee K.   Flesch M.   Kuhn-Regnier F.   Sudkamp M.   Bohm M.  

European Journal of Pharmacology, Vol. 294, Iss. 1, 1995-01 ,pp. : 17-27

Elsevier

Access to resources Recommend Favorite

Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin

By Pham I.   Gonzalez W.   Doucet J.   Fournie-Zaluski M.-C.   Roques B.P.   Michel J.-B.  

European Journal of Pharmacology, Vol. 296, Iss. 3, 1996-02 ,pp. : 267-276

Elsevier

Access to resources Recommend Favorite

Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

By Kjeldsen Sverre E   Lyle Paulette A   Tershakovec Andrew M   Devereux Richard B   Oparil Suzanne   Dahlöf Björn   de Faire Ulf   Fyhrquist Frej   Ibsen Hans   Kristianson Krister   Lederballe-Pedersen Ole   Lindholm Lars H   Nieminen Markku S   Omvik Per   Wedel Hans  

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 4, 2005-11 ,pp. : 729-745

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic targeting of the angiotensin-converting enzyme 2/Angiotensin-(1-7)/Mas cascade in the renin–angiotensin system: a patent review

By Ferreira Anderson J   Bader Michael   Santos Robson AS  

Expert Opinion on Therapeutic Patents, Vol. 22, Iss. 5, 2012-05 ,pp. : 567-574

Informa Healthcare

Access to resources Recommend Favorite